{
    "organizations": [],
    "uuid": "3e5c0d8745ea8da3770a11c15fc811101a1debc4",
    "author": "",
    "url": "https://www.reuters.com/article/brief-mylan-acquires-global-development/brief-mylan-acquires-global-development-marketing-rights-for-meloxicam-idUSFWN1RO0SJ",
    "ord_in_thread": 0,
    "title": "BRIEF-Mylan Acquires Global Development & Marketing Rights For Meloxicam",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 11, 2018 / 4:42 PM / Updated 23 minutes ago BRIEF-Mylan Acquires Global Development & Marketing Rights For Meloxicam Reuters Staff 1 Min Read \nApril 11 (Reuters) - Mylan NV: \n* MYLAN - ACQUIRED GLOBAL DEVELOPMENT & MARKETING RIGHTS FROM PRAYOG LABS TO BRING TO MARKET FAST-ACTING MELOXICAM AS PROPOSED NON-NARCOTIC ANALGESIC \n* MYLAN SAYS WILL BE SUBMITTING AN INVESTIGATIONAL NEW DRUG APPLICATION TO U.S. FDA FOR MELOXICAM Source text for Eikon: Further company coverage:",
    "published": "2018-04-11T19:41:00.000+03:00",
    "crawled": "2018-04-11T20:10:48.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "acquires",
        "global",
        "development",
        "marketing",
        "right",
        "meloxicam",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "mylan",
        "nv",
        "mylan",
        "acquired",
        "global",
        "development",
        "marketing",
        "right",
        "prayog",
        "lab",
        "bring",
        "market",
        "meloxicam",
        "proposed",
        "analgesic",
        "mylan",
        "say",
        "submitting",
        "investigational",
        "new",
        "drug",
        "application",
        "fda",
        "meloxicam",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}